Detalhe da pesquisa
1.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
N Engl J Med
; 383(15): 1425-1435, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966714
2.
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
Diabetes Obes Metab
; 25(1): 46-55, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111434
3.
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Diabetologia
; 64(6): 1256-1267, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33665685
4.
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Circulation
; 142(23): 2205-2215, 2020 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026243
5.
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
Diabetes Obes Metab
; 23(7): 1588-1593, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33687748
6.
Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study.
Diabetes Obes Metab
; 23(8): 1823-1833, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852202
7.
Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study.
Diabetes Obes Metab
; 23(8): 1956-1960, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852196
8.
Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study.
Diabetes Obes Metab
; 23(1): 39-48, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32845558
9.
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
Diabetes Obes Metab
; 22(12): 2276-2286, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32700421
10.
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Diabetes Obes Metab
; 21(4): 1027-1036, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30614616
11.
Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
Diabetes Obes Metab
; 21(11): 2474-2485, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31297947
12.
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Am Heart J
; 206: 11-23, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30290289
13.
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Diabetes Obes Metab
; 20(3): 520-529, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28857451
14.
Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
Diabetes Obes Metab
; 20(2): 389-399, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817227
15.
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
Diabetologia
; 65(5): 908-911, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35238955
16.
Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV.
Circulation
; 143(6): 602-605, 2021 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186063
17.
Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Diabetes Obes Metab
; 19(11): 1546-1554, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28449412
18.
[Determinants of the cost of initiation of insulin therapy type 2 diabetic patients in France: possible approaches to optimization]. / Déterminants des coûts du passage à linsuline en France chez le patient diabétique de type 2 : quelles pistes doptimisation ?
Sante Publique
; 28(6): 781-789, 2016 Dec 19.
Artigo
em Francês
| MEDLINE | ID: mdl-28155773
19.
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
N Engl J Med
; 362(16): 1463-76, 2010 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20228402
20.
Effect of valsartan on the incidence of diabetes and cardiovascular events.
N Engl J Med
; 362(16): 1477-90, 2010 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20228403